PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023GlobeNewsWire • 04/03/23
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023GlobeNewsWire • 03/30/23
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial ResultsGlobeNewsWire • 03/28/23
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial ResultsGlobeNewsWire • 03/16/23
PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint InhibitorGlobeNewsWire • 02/27/23
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™GlobeNewsWire • 02/16/23
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, VirusesGlobeNewsWire • 02/08/23
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies CongressGlobeNewsWire • 02/06/23
PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology ConferenceGlobeNewsWire • 01/13/23
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, GermanyGlobeNewsWire • 01/03/23
PDS Biotechnology's latest trial reports improved survival in advanced cancer patientsProactive Investors • 12/28/22
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 monthsGlobeNewsWire • 12/28/22
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck CancerGlobeNewsWire • 12/15/22
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Frank Bedu-Addo, CEO PDS Biotechnology CorporationAccesswire • 12/05/22
PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy CongressGlobeNewsWire • 11/21/22
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/22
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial ResultsGlobeNewsWire • 10/31/22